Pericardium News and Research

RSS

The term pericardium is derived from the Greek prefix peri- (“around”) and kardia (“heart”), implying a structure that envelops or encloses the heart. Morphologically, the pericardium is a fluid-filled sac-like structure that surrounds the heart.

Rituximab drug may be safe, effective for immunoglobulin G4-related disease treatment

Rituximab (Rituxan) — a drug commonly used rheumatoid arthritis, granulomatosis with polyangiitis (formerly Wegener's), and certain types of cancers — may be a safe and effective treatment for immunoglobulin G4-related disease (commonly called IgG4-RD), according to research presented this week at the American College of Rheumatology Annual Meeting in San Diego.

28 Oct 2013

Cancer patients who receive chest radiation should screen for heart disease every 5-10 years

Cancer patients who receive chest radiation should be screened for heart disease every 5-10 years, according to the European Association of Cardiovascular Imaging (EACVI) of the European Society of Cardiology (ESC) and the American Society of Echocardiography (ASE).

17 Jul 2013

Cancer patients who receive chest radiation should be screened for heart disease every 5-10 years

16 Jul 2013

Michigan's first cardio-oncology clinic launched to prevent heart problems

As cancer therapy becomes more effective and the number of cancer survivors increases, doctors are faced with a new challenge: ensuring patients have a healthy heart to enjoy the rest of their lives.

16 Apr 2013

Sorin Group’s Mitroflow valve receives Japanese PMDA approval

Sorin Group, a global medical company and a leader in the treatment of cardiovascular diseases, announced today that it received the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) approval for the Mitroflow Aortic Pericardial Heart Valve.

4 Dec 2012

Tricuspidization preferred for unicuspid aortic valve repair

Unicuspid aortic valves may be reconstructed with tricuspidization using glutaraldehyde-treated autologous pericardium, with excellent early results and no mortality or major morbidity, the results of a preliminary study suggest.

22 Oct 2012

Patients with early stage MPM may be eligible for aggressive multi-modality therapy

Patients with early stage malignant pleural mesothelioma (MPM), a cancer that develops in the lining of the lungs, may be eligible for aggressive multi-modality therapy involving surgery, radiotherapy and chemotherapy.

16 Mar 2012

Bovine collagen can enhance gum healing

Receding gums often result in tooth sensitivity and can lead to decay of the root and persistent inflammation of the gum. New research published in BioMed Central's open access journal Head & Face Medicine demonstrates that a novel method using bovine collagen is able to enhance gum healing. This resulted in thicker margins around the tooth and, in over half the cases, complete coverage of exposed roots.

5 Mar 2012

Researchers derive vessel-forming stem cells from amniotic fluid

Researchers at Rice University and Texas Children's Hospital have turned stem cells from amniotic fluid into cells that form blood vessels. Their success offers hope that such stem cells may be used to grow tissue patches to repair infant hearts.

7 Feb 2012

Cardiologist measures risk factors associated with CR

The cardiologist Aitor Jim-nez has managed to gather and characterise in detail 110 cases of cardiac rupture (CR), after spending 22 years (1978-2000) gathering data at the Hospital de Cruces, near Bilbao. It is one of the broadest anatomical series described in this respect. CR is the most serious complication of acute myocardial infarction; it is not very common, but when it does occur, it is mortal in practically all cases. So prevention, although difficult, seems more feasible than cure.

10 Jan 2012

Role of cardiovascular magnetic resonance in clinical cardiology

Cardiovascular Magnetic Resonance (CMR) has undergone substantial development and offers important advantages compared with other well-established imaging modalities.

3 Nov 2011

Sorin Group announces commercial availability of Perceval S aortic heart valve in Europe

Sorin Group, a global medical device company and a leader in the treatment of cardiovascular diseases, announces the commercial availability in Europe of the self- anchoring Perceval S aortic heart valve. The innovative next-generation valve represents the latest innovation in heart valve technology.

31 Jan 2011

Enrollment commences in multi-center clinical trial of CorMatrix ECM for Pericardial Closure

CorMatrix Cardiovascular, Inc., an Atlanta-based company dedicated to developing and delivering unique extracellular matrix (ECM) biomaterial devices that harness the body's innate ability to repair damaged cardiovascular tissue, announced today that Franciscan Alliance/St. Francis Heart Center in Indianapolis, Indiana is the first site to enroll a patient in the multi-center clinical trial of the CorMatrix ECM for Pericardial Closure to reduce the incidence of new onset postoperative atrial fibrillation.

13 Dec 2010

Researchers examine outcomes related to antiplatelet therapy in patients undergoing CEA

Despite the common clinical practice among surgeons to discontinue their patients' anti-platelet therapy prior to surgery, a recent study of patients undergoing carotid endarterectomy (CEA) indicated that this practice may be unnecessary.

13 Dec 2010

CorMatrix's ECM technology reduces postoperative atrial fibrillation in CABG patients

CorMatrix Cardiovascular, Inc., a medical device company dedicated to developing and delivering unique extracellular matrix (ECM) biomaterial devices that harness the body's innate ability to repair damaged cardiovascular tissue, announced today that a retrospective study demonstrated that reconstructing the pericardium using ECM Technology in patients undergoing primary isolated coronary artery bypass grafting (CABG) contributed to a statistically significant and clinically meaningful reduction in the rate of new onset postoperative atrial fibrillation.

26 Oct 2010

Implantation of new bioprosthetic-tissue valve in patients with severe aortic stenosis saves lives

Implantation of a new bioprosthetic-tissue valve into the hearts of patients who have severe aortic stenosis and are too sick or too old for open-heart surgery has been found to both save lives and improve the quality of those lives, according to a new multicenter study, to be published online at 2 p.m. Pacific time today in the New England Journal of Medicine.

23 Sep 2010

Perceval S Aortic Heart Valve early clinical results to be presented at 24th EACTS

Sorin Group, a global medical company and a leader in the treatment of cardiovascular diseases, announced today the presentation by Francois Laborde, MD, Professor of Cardiac Surgery, Institut Mutualiste Montsouris, Paris, France at the 24th EACTS Annual Meeting in Geneva, Switzerland of the early clinical results of the first 180 patients implanted with the Perceval S Aortic Heart Valve (investigational device).

15 Sep 2010

FDA approves CorMatrix ECM for Pericardial Closure

CorMatrix Cardiovascular, Inc., a medical device company developing and delivering unique extracellular matrix (ECM) biomaterial devices that harness the body's innate ability to repair damaged cardiovascular tissue, announced today that FDA has granted conditional approval for the start of a multi-center, prospective, randomized clinical trial to demonstrate the safety and efficacy of the CorMatrix ECM for Pericardial Closure to reduce the incidence of new onset postoperative atrial fibrillation.

13 Sep 2010

Synovis Life Technologies third-quarter net revenue increases 17% to $17.6 million

Synovis Life Technologies, Inc., today reported its financial results for the third quarter ended July 31, 2010.

25 Aug 2010

Synovis Life Technologies' second-quarter 2010 net revenue up 19%

Synovis Life Technologies, Inc., today reported record revenue for the second quarter ended April 30, 2010.

26 May 2010